Jessup Wealth Management Inc acquired a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 8,635 shares of the exchange traded fund’s stock, valued at approximately $1,053,000.
Several other hedge funds and other institutional investors have also made changes to their positions in XBI. AQR Capital Management LLC boosted its position in shares of SPDR S&P Biotech ETF by 77.1% during the first quarter. AQR Capital Management LLC now owns 4,978 shares of the exchange traded fund’s stock worth $404,000 after buying an additional 2,167 shares during the period. Marshall Wace LLP boosted its position in shares of SPDR S&P Biotech ETF by 102.3% during the second quarter. Marshall Wace LLP now owns 4,023 shares of the exchange traded fund’s stock worth $334,000 after buying an additional 179,029 shares during the period. The Manufacturers Life Insurance Company acquired a new position in shares of SPDR S&P Biotech ETF during the second quarter worth approximately $260,000. Ameriprise Financial Inc. boosted its position in shares of SPDR S&P Biotech ETF by 123.0% during the second quarter. Ameriprise Financial Inc. now owns 872,796 shares of the exchange traded fund’s stock worth $72,542,000 after buying an additional 481,408 shares during the period. Finally, EP Wealth Advisors LLC boosted its position in shares of SPDR S&P Biotech ETF by 3.7% during the second quarter. EP Wealth Advisors LLC now owns 5,379 shares of the exchange traded fund’s stock worth $446,000 after buying an additional 193 shares during the period.
SPDR S&P Biotech ETF Price Performance
Shares of NYSEARCA:XBI opened at $128.85 on Thursday. SPDR S&P Biotech ETF has a 12 month low of $80.90 and a 12 month high of $139.19. The stock has a market cap of $8.22 billion, a price-to-earnings ratio of 11.47 and a beta of 0.85. The stock’s 50 day moving average price is $132.43 and its 200 day moving average price is $126.96.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Further Reading
- Five stocks we like better than SPDR S&P Biotech ETF
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
